Su G F, Brahmbhatt H N, Wehland J, Rohde M, Timmis K N
Department of Microbiology, GBF, National Research Centre for Biotechnology, Braunschweig, Germany.
Infect Immun. 1992 Aug;60(8):3345-59. doi: 10.1128/iai.60.8.3345-3359.1992.
The complete Shiga toxin B subunit and two N-terminal segments of the B subunit have been inserted into a cell surface exposed loop of the LamB protein, and expression of the hybrid proteins from three different promoter systems, i.e., (i) an in vitro-inducible tac promoter that provides high-level expression, (ii) the iron-regulated aerobactin promoter presumably induced in vivo under the iron-limiting conditions of the intestinal mucosal environment, and (iii) a synthetic, modified beta-lactamase promoter providing moderate level constitutive expression, has been analyzed in Escherichia coli, Salmonella typhimurium, and attenuated antigen carrier strains of S. typhimurium (aroA mutants). The hybrid vaccine strains were used to immunize mice by the oral and intraperitoneal routes. S. typhimurium aroA mutants apparently have a membrane export defect which prevents the transport of LamB and its derivatives across the cytoplasmic membrane. High-level expression of hybrid proteins through use of the tac promoter proved deleterious to the vaccine strains and prevented the production of viable cells at reasonable cell densities. The lower levels of gene expression observed with the beta-lactamase and aerobactin promoters did not have this effect. Immunization of mice with S. typhimurium aroA strains carrying the hybrid genes expressed from these two promoters resulted in significant B subunit-specific mucosal and serum antibody responses. This suggests that such expression systems may be useful when incorporated into candidate antidysentery live oral vaccines for inducing protection against the effect of Shiga toxin in infections caused by Shigella dysenteriae 1 and other Shiga toxin-or Shiga-like toxin-producing pathogens.
志贺毒素B亚基的完整序列以及该B亚基的两个N端片段已被插入到LamB蛋白的一个细胞表面暴露环中,并且已经在大肠杆菌、鼠伤寒沙门氏菌以及鼠伤寒沙门氏菌(aroA突变体)的减毒抗原载体菌株中分析了来自三种不同启动子系统的杂合蛋白的表达情况,即:(i)一种体外可诱导的tac启动子,它能提供高水平表达;(ii)铁调节的气杆菌素启动子,推测在肠道黏膜环境的铁限制条件下在体内被诱导;(iii)一种合成的、经过修饰的β-内酰胺酶启动子,提供中等水平的组成型表达。这些杂合疫苗菌株通过口服和腹腔注射途径用于免疫小鼠。鼠伤寒沙门氏菌aroA突变体显然存在膜输出缺陷,这阻止了LamB及其衍生物穿过细胞质膜。通过使用tac启动子实现的杂合蛋白的高水平表达被证明对疫苗菌株有害,并阻止了在合理细胞密度下产生活细胞。使用β-内酰胺酶启动子和气杆菌素启动子观察到的较低水平的基因表达没有这种影响。用携带从这两个启动子表达的杂合基因的鼠伤寒沙门氏菌aroA菌株免疫小鼠,导致了显著的B亚基特异性黏膜和血清抗体反应。这表明,当将此类表达系统纳入候选抗痢疾活口服疫苗中以诱导针对痢疾志贺氏菌1型和其他产生志贺毒素或志贺样毒素的病原体感染中志贺毒素作用的保护时,可能会有用。